Humoral And Cellular Tolerization Approaches Against Au*
针对 Au* 的体液和细胞耐受方法
基本信息
- 批准号:6872007
- 负责人:
- 金额:$ 74.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-30 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
After carefully evaluating the merits, potential pitfalls, concerns and failures of the strategies so far proposed to treat autoimmune diseases, it was concluded that recombinant antibody and dendritic cell-based approaches would be clinically translatable modalities with the greatest likelihood of success during treatment, combined with the least concern of deleterious side effects. Importantly, the investigators collaborating in this proposal have themselves, or are collaborating with others at the University of Pittsburgh who have exceptional expertise in these approaches. This application will provide further insights into the basic mechanisms of action of the proposed approaches, in itself a compelling rationale for their selection and evaluation. To better organize these studies, it was also concluded that an Autoimmunity Center of Excellence may represent the most appropriate "umbrella" under which to consolidate the efforts of the interested clinicians and scientists of the University of Pittsburgh. The complexity of studying and developing new therapeutic approaches to treating autoimmune diseases requires a modern, multidisciplinary research climate. The synchronization of both the expertise and the technology available among the investigators within this university who are interested in the same scientific area, i.e., autoimmunity, is necessary in order to maximize the use of all of the resources in the most cost effective and academically efficient manner. Moreover the University of Pittsburgh will greatly benefit from a forum specifically dedicated to the study of autoimmunity, where both junior and established investigators within different departments and institutions, and with interdisciplinary expertise, can be drawn together with interested clinicians so that bench-to-bedside transfer can be fostered more efficiently. In order to encourage young researchers to devote their careers to the study of autoimmune ailments, especially those that affect children, it is here proposed to build an Autoimmune Center of Excellence with the specific belief that fostering of this type of career is easier within a scientifically challenging atmosphere of collegiality and intellectual discourse. Finally, having an Autoimmunity Center of Excellence in Pittsburgh entirely dedicated to a single philosophical and scientific goal: "understanding, preventing and eventually curing autoimmune diseases" will allow the creation of new scientific leads that will form the basis for more promising clinical trials.
描述(由申请人提供):
在仔细评估了迄今为止提出的治疗自身免疫性疾病的策略的优点、潜在陷阱、关注点和失败之后,得出的结论是,基于重组抗体和树突状细胞的方法将是临床上可转化的模式,在治疗期间具有最大的成功可能性,并且对有害副作用的关注最少。重要的是,参与这项提议的研究人员本身或正在与匹兹堡大学的其他人合作,他们在这些方法方面具有特殊的专业知识。这一应用将进一步深入了解拟议办法的基本作用机制,这本身就是选择和评价这些办法的令人信服的理由。为了更好地组织这些研究,还得出结论,自身免疫卓越中心可能是最合适的“保护伞”,可以巩固匹兹堡大学感兴趣的临床医生和科学家的努力。研究和开发新的治疗方法来治疗自身免疫性疾病的复杂性需要一个现代化的,多学科的研究环境。在这所大学内对同一科学领域感兴趣的研究人员之间的专业知识和技术的同步,即,为了以最具成本效益和学术效率的方式最大限度地利用所有资源,自身免疫是必要的。 此外,匹兹堡大学将从专门致力于自身免疫研究的论坛中受益匪浅,在该论坛中,不同部门和机构内的初级和成熟的研究人员以及跨学科的专业知识可以与感兴趣的临床医生聚集在一起,以便能够更有效地促进从工作台到床边的转移。为了鼓励年轻的研究人员致力于自身免疫性疾病的研究,特别是那些影响儿童的疾病,这里建议建立一个自身免疫卓越中心,具体的信念是培养这种类型的职业生涯更容易在科学上具有挑战性的气氛中的合议和知识话语。最后,在匹兹堡建立一个自身免疫卓越中心,完全致力于一个哲学和科学目标:“理解、预防并最终治愈自身免疫性疾病”,这将有助于创造新的科学线索,为更有前途的临床试验奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MASSIMO M. TRUCCO其他文献
MASSIMO M. TRUCCO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MASSIMO M. TRUCCO', 18)}}的其他基金
Humoral And Cellular Tolerization Approaches Against Au*
针对 Au* 的体液和细胞耐受方法
- 批准号:
6803537 - 财政年份:2003
- 资助金额:
$ 74.89万 - 项目类别:
Humoral And Cellular Tolerization Approaches Against Au*
针对 Au* 的体液和细胞耐受方法
- 批准号:
6684628 - 财政年份:2003
- 资助金额:
$ 74.89万 - 项目类别:
Humoral And Cellular Tolerization Approaches Against Autoimmunity
对抗自身免疫的体液和细胞耐受方法
- 批准号:
7228440 - 财政年份:2003
- 资助金额:
$ 74.89万 - 项目类别:
Humoral And Cellular Tolerization Approaches Against Au*
针对 Au* 的体液和细胞耐受方法
- 批准号:
7038210 - 财政年份:2003
- 资助金额:
$ 74.89万 - 项目类别:
Gene-engineered dendritic cell therapy for diabetics
针对糖尿病患者的基因工程树突状细胞疗法
- 批准号:
6666777 - 财政年份:2002
- 资助金额:
$ 74.89万 - 项目类别:
Optical Imaging of Beta-Cell Function and Engraftment
β 细胞功能和植入的光学成像
- 批准号:
6666714 - 财政年份:2002
- 资助金额:
$ 74.89万 - 项目类别:
Gene-engineered dendritic cell therapy for diabetics
针对糖尿病患者的基因工程树突状细胞疗法
- 批准号:
7119507 - 财政年份:2002
- 资助金额:
$ 74.89万 - 项目类别:
Optical Imaging of Beta-Cell Function and Engraftment
β 细胞功能和植入的光学成像
- 批准号:
6574526 - 财政年份:2002
- 资助金额:
$ 74.89万 - 项目类别:
Gene-engineered dendritic cell therapy for diabetics
针对糖尿病患者的基因工程树突状细胞疗法
- 批准号:
7085769 - 财政年份:2002
- 资助金额:
$ 74.89万 - 项目类别:
Gene-engineered dendritic cell therapy for diabetics
针对糖尿病患者的基因工程树突状细胞疗法
- 批准号:
6575957 - 财政年份:2002
- 资助金额:
$ 74.89万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 74.89万 - 项目类别:
Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 74.89万 - 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 74.89万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 74.89万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 74.89万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 74.89万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 74.89万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 74.89万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 74.89万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 74.89万 - 项目类别: